Cronos Group Inc.
NASDAQ:CRONDrug Manufacturers - Specialty & Generic
-$0.02 today
- Market cap
- $1.16B
- Beta
- 1.25
- P/E (TTM)
- -488.3
- EPS (TTM)
- -$0.01
Volume 1.13M
Average 1.51M
CRON Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Cronos Group Inc.NASDAQ: CRON
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $3.68M rose 29.4% year over year, ahead of the -92.0% change in trailing-twelve-month depreciation & amortization. Over 3 fiscal years it compounded at +3.3% a year.
Context
- Depreciation & amortization amounted to 9.7% of revenue in FY2025, up 1.8 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +29.4% holds above the trailing-twelve-month pace of -92.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 14.48M USD
- Year-over-year change
- +55.1%
- 4-year CAGR
- -1.5%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.48M | +55.1% |
| FY2024 | 2024-12-31 | 9.34M | +15.1% |
| FY2023 | 2023-12-31 | 8.11M | -38.2% |
| FY2022 | 2022-12-31 | 13.12M | -14.8% |
| FY2021 | 2021-12-31 | 15.4M | — |
Depreciation & Amortization vs competitors
How CRON compares with its peers on the latest reported figures
- CRON's LTM Mar 2026 depreciation & amortization of $835.37K is the 10th largest of the 11 companies compared; the peer median is $13.02M.
- Its year-over-year change of -92.0% is the lowest of 11, against a peer median of +13.0%.
- Depreciation & amortization amounts to 0.4% of revenue for CRON, versus a peer median of 5.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $227.86M | +19.7% | +16.7% | 28.6% | |
| LTM Mar 2026 | $91.19M | +11.8% | -0.2% | 12.4% | |
| LTM Mar 2026 | $57.48M | +44.0% | +30.0% | 8.0% | |
| LTM Mar 2026 | $40.2M | +14.2% | +8.7% | 3.9% | |
| LTM Aug 2026 | $15.87M | -14.3% | +20.4% | 2.3% | |
| LTM Jun 2026 | $10.17M | -10.7% | +6.1% | 9.7% | |
| LTM Mar 2026 | $1.43M | +81.6% | +20.2% | 1.7% | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1M | +7.4% | +296.1% | 5.0% |
BBOTBridgeBio Oncology Therapeutics Inc. | LTM Mar 2026 | $977K | +526.3% | — | — |
| LTM Mar 2026 | $835.37K | -92.0% | +3.3% | 0.4% | |
| LTM Mar 2026 | $566K | -25.3% | +0.7% | 0.3% | |
| Peer median (excluding CRON) | $13.02M | +13.0% | +16.7% | 5.0% | |
Competitors are the stored peer set for CRON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (397.2M) | (168.73M) | (74.55M) | 40.02M | (2.93M) |
| Depreciation & Amortization | 15.4M | 13.12M | 8.11M | 9.34M | 14.48M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 10.15M | 15.12M | 8.77M | 8.7M | 7.05M |
| Change in Working Capital | (4.84M) | 15.66M | (26.47M) | (311K) | (35.02M) |
| Accounts Receivables | (12.16M) | (8.55M) | (6.59M) | (917K) | (26.2M) |
| Inventory | 11.57M | (7.22M) | 7.4M | 5.28M | (10.58M) |
| Accounts Payables | (1.6M) | (863K) | (773K) | (7.45M) | 1.13M |
| Other Working Capital | (2.65M) | 32.29M | (26.51M) | 2.77M | 636.96K |
| Other Non-Cash Items | 222.88M | 35.89M | 41.31M | (38.9M) | 42.73M |
| Operating Cash Flow | (153.62M) | (88.95M) | (42.84M) | 18.84M | 26.32M |
| Capital Expenditures | (12.26M) | (5.03M) | (3.42M) | (13.15M) | (26.17M) |
| Acquisitions (Net) | 0 | 0 | 0 | 5.71M | 2.9M |
| Purchases of Investments | (230M) | (271.38M) | (608.25M) | (8.34M) | (59.44M) |
| Sales of Investments | 215.3M | 268.87M | 532.84M | 181.9M | 5.15M |
| Other Investing Activities | (3.06M) | 4.12M | 18.42M | 8.41M | 0 |
| Investing Cash Flow | (28.9M) | (1.84M) | (59.5M) | 175.15M | (77.9M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (9.91M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (13.44M) | (2.9M) | (1.03M) | (1.23M) | (10.34M) |
| Financing Cash Flow | (13.44M) | (2.9M) | (1.03M) | (1.23M) | (20.25M) |
| Effect of Forex Changes | 4.91M | (28.64M) | 8.01M | (3.25M) | 3.89M |
| Net Change in Cash | (191.05M) | (122.33M) | (95.35M) | 189.51M | (67.94M) |
| Free Cash Flow | (165.88M) | (93.98M) | (46.26M) | 5.69M | 151.61K |
Cronos Group Inc.
NASDAQ:CRON
Intrinsic Alpha fair value
Locked
Current Price
$3.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.